Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$159.86
-0.5%
$163.44
$143.13
$168.85
$384.73B0.526.99 million shs8.27 million shs
Kenvue Inc. stock logo
KVUE
Kenvue
$22.93
+0.2%
$22.48
$17.67
$23.55
$43.91B1.418.12 million shs34.41 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$829.84
-2.0%
$916.20
$547.61
$972.53
$788.68B0.423.05 million shs6.57 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$111.96
-1.1%
$125.25
$94.73
$148.15
$502.42B0.424.36 million shs8.45 million shs
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$334.75
$332.85
$157.00
$334.90
$12.57B0.88968,088 shsN/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.30%-3.16%-0.86%-0.09%+8.28%
Kenvue Inc. stock logo
KVUE
Kenvue
+0.53%+0.66%-0.99%+22.92%+23.15%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-6.32%-6.21%-4.37%+1.74%+52.89%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.10%-2.13%-4.88%-14.57%+17.26%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
0.00%0.00%0.00%0.00%+62.30%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.9682 of 5 stars
3.35.04.23.92.62.51.9
Kenvue Inc. stock logo
KVUE
Kenvue
3.8824 of 5 stars
2.15.02.50.04.01.71.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8578 of 5 stars
3.43.00.84.02.91.73.1
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.2793 of 5 stars
3.45.01.70.02.50.03.1
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
1.9999 of 5 stars
1.10.00.04.60.61.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.54
Moderate Buy$175.9310.05% Upside
Kenvue Inc. stock logo
KVUE
Kenvue
2.25
Hold$22.64-1.28% Downside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$1,009.0021.59% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.86
Moderate Buy$144.5029.06% Upside
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
2.10
Hold$320.50-4.26% Downside

Current Analyst Ratings

Latest JNJ, SWAV, KVUE, NVO, and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/31/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$1,025.00 ➝ $975.00
10/31/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,150.00 ➝ $1,100.00
10/25/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1,060.00 ➝ $1,250.00
10/22/2024
Kenvue Inc. stock logo
KVUE
Kenvue
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $27.00
10/17/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$1,100.00
10/17/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$160.00 ➝ $156.00
10/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$180.00 ➝ $185.00
10/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
10/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$163.00 ➝ $166.00
10/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$178.00 ➝ $181.00
10/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$169.00 ➝ $175.00
(Data available from 10/31/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$87.70B4.39$13.37 per share11.96$28.57 per share5.60
Kenvue Inc. stock logo
KVUE
Kenvue
$15.48B2.84$1.57 per share14.59$5.85 per share3.92
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$38.92B20.26$6.96 per share119.21$11.44 per share72.54
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$258.00B1.95$2.97 per share37.66$3.45 per share32.45
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$787.97M15.95$4.31 per share77.61$20.02 per share16.72

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.0423.1315.142.9019.14%35.46%14.32%1/28/2025 (Estimated)
Kenvue Inc. stock logo
KVUE
Kenvue
$1.66B$0.7839.5318.803.007.23%21.80%8.61%11/7/2024 (Confirmed)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$6.79102.2034.233.2418.86%67.52%12.76%2/4/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$12.15B$2.9238.3426.781.4834.86%87.43%28.01%11/6/2024 (Confirmed)
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$147.28M$4.2878.2154.342.4320.75%24.79%11.95%N/A

Latest JNJ, SWAV, KVUE, NVO, and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/7/2024N/A
Kenvue Inc. stock logo
KVUE
Kenvue
$0.27N/A-$0.27N/AN/AN/A  
11/6/2024N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.91N/A-$0.91N/AN/AN/A  
10/30/2024Q3 24
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1.52$1.18-$0.34$1.29$12.09 billion$11.44 billion      
10/15/2024Q3 2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.21$2.42+$0.21$3.73$22.17 billion$22.47 billion    
8/8/2024Q2 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.64$3.92+$1.28$4.56$9.83 billion$11.30 billion
8/7/2024Q2 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.71$0.65-$0.06$0.65$9.91 billion$9.82 billion
8/6/2024Q2 2024
Kenvue Inc. stock logo
KVUE
Kenvue
$0.28$0.32+$0.04$0.61$3.93 billion$4.00 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.963.10%+5.70%30.92%63 Years
Kenvue Inc. stock logo
KVUE
Kenvue
$0.823.58%N/A105.13%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.63%+15.15%76.58%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.720.64%+16.52%24.66%N/A
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
N/AN/AN/AN/AN/A

Latest JNJ, SWAV, KVUE, NVO, and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/15/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.07%11/26/202411/26/202412/10/2024
10/28/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.300.58%11/15/202411/15/202412/10/2024
10/17/2024
Kenvue Inc. stock logo
KVUE
Kenvue
quarterly$0.20503.77%11/13/202411/13/202411/27/2024
8/6/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.51260.7%8/16/20248/16/20248/26/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.07
0.85
Kenvue Inc. stock logo
KVUE
Kenvue
0.69
0.99
0.68
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.74
1.11
0.87
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.46
0.94
0.75
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
0.97
13.81
12.61

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Kenvue Inc. stock logo
KVUE
Kenvue
97.64%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
95.35%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Kenvue Inc. stock logo
KVUE
Kenvue
0.17%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
3.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.40 billionOptionable
Kenvue Inc. stock logo
KVUE
Kenvue
22,0001.91 billion1.91 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.41 million949.19 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
63,3704.49 billion4.48 billionOptionable
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
1,46837.54 million36.27 millionOptionable

JNJ, SWAV, KVUE, NVO, and LLY Headlines

Recent News About These Companies

Shockwave E8 Peripheral IVL Catheter Launched
GRPM: Why This Mid-Cap GARP ETF Deserves An Upgrade

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines

Company Descriptions

Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Kenvue logo

Kenvue

NYSE:KVUE
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Novo Nordisk A/S logo

Novo Nordisk A/S

NYSE:NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Shockwave Medical logo

Shockwave Medical

NASDAQ:SWAV
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.